{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T19:19:04Z","timestamp":1792955944678,"version":"4.5.0"},"reference-count":111,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2011,10,28]],"date-time":"2011-10-28T00:00:00Z","timestamp":1319760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2011,10,28]],"date-time":"2011-10-28T00:00:00Z","timestamp":1319760000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1007\/s00262-011-1126-z","type":"journal-article","created":{"date-parts":[[2011,10,27]],"date-time":"2011-10-27T19:40:56Z","timestamp":1319744456000},"page":"1655-1668","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Antigens in chronic myeloid leukemia: implications for vaccine development"],"prefix":"10.1007","volume":"60","author":[{"given":"Michal","family":"\u0160mahel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,10,28]]},"reference":[{"key":"1126_CR1","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1182\/blood-2008-03-144790","volume":"113","author":"A Quintas-Cardama","year":"2009","unstructured":"Quintas-Cardama A, Cortes J (2009) Molecular biology of bcr-abl1-positive chronic myeloid leukemia. Blood 113:1619\u20131630","journal-title":"Blood"},{"key":"1126_CR2","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/nrc2368","volume":"8","author":"M Savona","year":"2008","unstructured":"Savona M, Talpaz M (2008) Getting to the stem of chronic myeloid leukaemia. Nat Rev Cancer 8:341\u2013350","journal-title":"Nat Rev Cancer"},{"key":"1126_CR3","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1159\/000046636","volume":"107","author":"B Johansson","year":"2002","unstructured":"Johansson B, Fioretos T, Mitelman F (2002) Cytogenetic and molecular genetic evolution of chronic myeloid leukemia. Acta Haematol 107:76\u201394","journal-title":"Acta Haematol"},{"key":"1126_CR4","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1056\/NEJMoa040258","volume":"351","author":"CH Jamieson","year":"2004","unstructured":"Jamieson CH, Ailles LE, Dylla SJ et al (2004) Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med 351:657\u2013667","journal-title":"N Engl J Med"},{"key":"1126_CR5","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.2174\/092986709788186147","volume":"16","author":"R Gangemi","year":"2009","unstructured":"Gangemi R, Paleari L, Orengo AM, Cesario A, Chessa L, Ferrini S, Russo P (2009) Cancer stem cells: a new paradigm for understanding tumor growth and progression and drug resistance. Curr Med Chem 16:1688\u20131703","journal-title":"Curr Med Chem"},{"key":"1126_CR6","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1177\/107327480901600206","volume":"16","author":"J Pinilla-Ibarz","year":"2009","unstructured":"Pinilla-Ibarz J, Shah B, Dubovsky JA (2009) The biological basis for immunotherapy in patients with chronic myelogenous leukemia. Cancer Control 16:141\u2013152","journal-title":"Cancer Control"},{"key":"1126_CR7","doi-asserted-by":"publisher","first-page":"5489","DOI":"10.1158\/0008-5472.CAN-07-0302","volume":"67","author":"KM Brauer","year":"2007","unstructured":"Brauer KM, Werth D, von Schwarzenberg K, Bringmann A, Kanz L, Grunebach F, Brossart P (2007) BCR-ABL activity is critical for the immunogenicity of chronic myelogenous leukemia cells. Cancer Res 67:5489\u20135497","journal-title":"Cancer Res"},{"key":"1126_CR8","doi-asserted-by":"publisher","first-page":"2556","DOI":"10.1182\/blood-2007-01-071001","volume":"110","author":"F Scheich","year":"2007","unstructured":"Scheich F, Duyster J, Peschel C, Bernhard H (2007) The immunogenicity of Bcr-Abl expressing dendritic cells is dependent on the Bcr-Abl kinase activity and dominated by Bcr-Abl regulated antigens. Blood 110:2556\u20132560","journal-title":"Blood"},{"key":"1126_CR9","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1007\/s12185-011-0781-3","volume":"93","author":"K Rezvani","year":"2011","unstructured":"Rezvani K (2011) Peptide vaccine therapy for leukemia. Int J Hematol 93:274\u2013280","journal-title":"Int J Hematol"},{"key":"1126_CR10","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/gb-2003-4-5-p3","volume":"4","author":"G Dennis Jr","year":"2003","unstructured":"Dennis G Jr, Sherman BT, Hosack DA, Yang J, Gao W, Lane HC, Lempicki RA (2003) DAVID: database for annotation, visualization, and integrated discovery. Genome Biol 4:3","journal-title":"Genome Biol"},{"key":"1126_CR11","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/nprot.2008.211","volume":"4","author":"DW Huang","year":"2009","unstructured":"Huang DW, Sherman BT, Lempicki RA (2009) Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4:44\u201357","journal-title":"Nat Protoc"},{"key":"1126_CR12","doi-asserted-by":"crossref","first-page":"374","DOI":"10.2144\/03342mt01","volume":"34","author":"AI Saeed","year":"2003","unstructured":"Saeed AI, Sharov V, White J et al (2003) TM4: a free, open-source system for microarray data management and analysis. Biotechniques 34:374\u2013378","journal-title":"Biotechniques"},{"key":"1126_CR13","doi-asserted-by":"crossref","first-page":"4938","DOI":"10.1182\/blood.V90.12.4938","volume":"90","author":"KP Papadopoulos","year":"1997","unstructured":"Papadopoulos KP, Suciu-Foca N, Hesdorffer CS, Tugulea S, Maffei A, Harris PE (1997) Naturally processed tissue- and differentiation stage-specific autologous peptides bound by HLA class I and II molecules of chronic myeloid leukemia blasts. Blood 90:4938\u20134946","journal-title":"Blood"},{"key":"1126_CR14","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1038\/sj.leu.2404234","volume":"20","author":"AJ Knights","year":"2006","unstructured":"Knights AJ, Weinzierl AO, Flad T, Guinn BA, Mueller L, Mufti GJ, Stevanovic S, Pawelec G (2006) A novel MHC-associated proteinase 3 peptide isolated from primary chronic myeloid leukaemia cells further supports the significance of this antigen for the immunotherapy of myeloid leukaemias. Leukemia 20:1067\u20131072","journal-title":"Leukemia"},{"key":"1126_CR15","doi-asserted-by":"publisher","first-page":"2014","DOI":"10.1111\/j.1349-7006.2009.01303.x","volume":"100","author":"OL Caballero","year":"2009","unstructured":"Caballero OL, Chen YT (2009) Cancer\/testis (CT) antigens: potential targets for immunotherapy. Cancer Sci 100:2014\u20132021","journal-title":"Cancer Sci"},{"key":"1126_CR16","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1111\/j.1600-0609.2008.01053.x","volume":"80","author":"J Greiner","year":"2008","unstructured":"Greiner J, Schmitt M (2008) Leukemia-associated antigens as target structures for a specific immunotherapy in chronic myeloid leukemia. Eur J Haematol 80:461\u2013468","journal-title":"Eur J Haematol"},{"key":"1126_CR17","doi-asserted-by":"publisher","first-page":"227","DOI":"10.2217\/imt.10.2","volume":"2","author":"V Vonka","year":"2010","unstructured":"Vonka V (2010) Immunotherapy of chronic myeloid leukemia: present state and future prospects. Immunotherapy 2:227\u2013241","journal-title":"Immunotherapy"},{"key":"1126_CR18","doi-asserted-by":"publisher","first-page":"16280","DOI":"10.1073\/pnas.1004408107","volume":"107","author":"M Jaras","year":"2010","unstructured":"Jaras M, Johnels P, Hansen N et al (2010) Isolation and killing of candidate chronic myeloid leukemia stem cells by antibody targeting of IL-1 receptor accessory protein. Proc Natl Acad Sci USA 107:16280\u201316285","journal-title":"Proc Natl Acad Sci USA"},{"key":"1126_CR19","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1038\/leu.2010.325","volume":"25","author":"AS Yong","year":"2011","unstructured":"Yong AS, Stephens N, Weber G et al (2011) Improved outcome following allogeneic stem cell transplantation in chronic myeloid leukemia is associated with higher expression of BMI-1 and immune responses to BMI-1 protein. Leukemia 25:629\u2013637","journal-title":"Leukemia"},{"key":"1126_CR20","doi-asserted-by":"publisher","first-page":"5892","DOI":"10.1158\/0008-5472.CAN-05-2868","volume":"66","author":"F Grunebach","year":"2006","unstructured":"Grunebach F, Mirakaj V, Mirakaj V, Muller MR, Brummendorf T, Brossart P (2006) BCR-ABL is not an immunodominant antigen in chronic myelogenous leukemia. Cancer Res 66:5892\u20135900","journal-title":"Cancer Res"},{"key":"1126_CR21","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/S0145-2126(98)00171-4","volume":"23","author":"HG Drexler","year":"1999","unstructured":"Drexler HG, MacLeod RA, Uphoff CC (1999) Leukemia cell lines: in vitro models for the study of Philadelphia chromosome-positive leukemia. Leuk Res 23:207\u2013215","journal-title":"Leuk Res"},{"key":"1126_CR22","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1158\/1078-0432.CCR-09-2046","volume":"16","author":"BD Smith","year":"2010","unstructured":"Smith BD, Kasamon YL, Kowalski J et al (2010) K562\/GM-CSF immunotherapy reduces tumor burden in chronic myeloid leukemia patients with residual disease on imatinib mesylate. Clin Cancer Res 16:338\u2013347","journal-title":"Clin Cancer Res"},{"key":"1126_CR23","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1038\/sj.leu.2403749","volume":"19","author":"A Andersson","year":"2005","unstructured":"Andersson A, Eden P, Lindgren D et al (2005) Gene expression profiling of leukemic cell lines reveals conserved molecular signatures among subtypes with specific genetic aberrations. Leukemia 19:1042\u20131050","journal-title":"Leukemia"},{"key":"1126_CR24","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1080\/10428190801896194","volume":"49","author":"S Schmidt","year":"2008","unstructured":"Schmidt S, Gastl G, Wolf D (2008) Possible role for gene expression profiling in predicting responses to conventional or targeted drugs in patients with chronic myeloid leukemia. Leuk Lymphoma 49:643\u2013647","journal-title":"Leuk Lymphoma"},{"key":"1126_CR25","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.beha.2009.04.002","volume":"22","author":"AS Yong","year":"2009","unstructured":"Yong AS, Melo JV (2009) The impact of gene profiling in chronic myeloid leukaemia. Best Pract Res Clin Haematol 22:181\u2013190","journal-title":"Best Pract Res Clin Haematol"},{"key":"1126_CR26","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1038\/sj.leu.2404549","volume":"21","author":"E Diaz-Blanco","year":"2007","unstructured":"Diaz-Blanco E, Bruns I, Neumann F et al (2007) Molecular signature of CD34(+) hematopoietic stem and progenitor cells of patients with CML in chronic phase. Leukemia 21:494\u2013504","journal-title":"Leukemia"},{"key":"1126_CR27","first-page":"459","volume":"90","author":"LC Crossman","year":"2005","unstructured":"Crossman LC, Mori M, Hsieh YC et al (2005) In chronic myeloid leukemia white cells from cytogenetic responders and non-responders to imatinib have very similar gene expression signatures. Haematologica 90:459\u2013464","journal-title":"Haematologica"},{"key":"1126_CR28","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1182\/blood-2005-05-2155","volume":"107","author":"AS Yong","year":"2006","unstructured":"Yong AS, Szydlo RM, Goldman JM, Apperley JF, Melo JV (2006) Molecular profiling of CD34+ cells identifies low expression of CD7, along with high expression of proteinase 3 or elastase, as predictors of longer survival in patients with CML. Blood 107:205\u2013212","journal-title":"Blood"},{"key":"1126_CR29","doi-asserted-by":"publisher","first-page":"2794","DOI":"10.1073\/pnas.0510423103","volume":"103","author":"JP Radich","year":"2006","unstructured":"Radich JP, Dai H, Mao M et al (2006) Gene expression changes associated with progression and response in chronic myeloid leukemia. Proc Natl Acad Sci USA 103:2794\u20132799","journal-title":"Proc Natl Acad Sci USA"},{"key":"1126_CR30","doi-asserted-by":"publisher","first-page":"5191","DOI":"10.1182\/blood-2008-08-176016","volume":"114","author":"RM Lemoli","year":"2009","unstructured":"Lemoli RM, Salvestrini V, Bianchi E et al (2009) Molecular and functional analysis of the stem cell compartment of chronic myelogenous leukemia reveals the presence of a CD34\u2212 cell population with intrinsic resistance to imatinib. Blood 114:5191\u20135200","journal-title":"Blood"},{"key":"1126_CR31","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1182\/blood-2009-03-210732","volume":"115","author":"SK McWeeney","year":"2010","unstructured":"McWeeney SK, Pemberton LC, Loriaux MM et al (2010) A gene expression signature of CD34+ cells to predict major cytogenetic response in chronic-phase chronic myeloid leukemia patients treated with imatinib. Blood 115:315\u2013325","journal-title":"Blood"},{"key":"1126_CR32","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.compbiolchem.2010.06.003","volume":"34","author":"FJ Burguillo","year":"2010","unstructured":"Burguillo FJ, Martin J, Barrera I, Bardsley WG (2010) Meta-analysis of microarray data: the case of imatinib resistance in chronic myelogenous leukemia. Comput Biol Chem 34:184\u2013192","journal-title":"Comput Biol Chem"},{"key":"1126_CR33","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s00262-009-0757-9","volume":"59","author":"R Liu","year":"2010","unstructured":"Liu R, Mitchell DA (2010) Survivin as an immunotherapeutic target for adult and pediatric malignant brain tumors. Cancer Immunol Immunother 59:183\u2013193","journal-title":"Cancer Immunol Immunother"},{"key":"1126_CR34","doi-asserted-by":"crossref","first-page":"21193","DOI":"10.1016\/S0021-9258(19)36816-4","volume":"267","author":"AB Sturrock","year":"1992","unstructured":"Sturrock AB, Franklin KF, Rao G, Marshall BC, Rebentisch MB, Lemons RS, Hoidal JR (1992) Structure, chromosomal assignment, and expression of the gene for proteinase-3. The Wegener\u2019s granulomatosis autoantigen. J Biol Chem 267:21193\u201321199","journal-title":"J Biol Chem"},{"key":"1126_CR35","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1111\/j.1365-2141.1995.tb03297.x","volume":"89","author":"R Dengler","year":"1995","unstructured":"Dengler R, Munstermann U, al-Batran S, Hausner I, Faderl S, Nerl C, Emmerich B (1995) Immunocytochemical and flow cytometric detection of proteinase 3 (myeloblastin) in normal and leukaemic myeloid cells. Br J Haematol 89:250\u2013257","journal-title":"Br J Haematol"},{"key":"1126_CR36","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1046\/j.1365-2141.2002.03261.x","volume":"116","author":"N Hosen","year":"2002","unstructured":"Hosen N, Sonoda Y, Oji Y et al (2002) Very low frequencies of human normal CD34+ haematopoietic progenitor cells express the Wilms\u2019 tumour gene WT1 at levels similar to those in leukaemia cells. Br J Haematol 116:409\u2013420","journal-title":"Br J Haematol"},{"key":"1126_CR37","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1038\/leu.2008.161","volume":"22","author":"AS Yong","year":"2008","unstructured":"Yong AS, Keyvanfar K, Eniafe R, Savani BN, Rezvani K, Sloand EM, Goldman JM, Barrett AJ (2008) Hematopoietic stem cells and progenitors of chronic myeloid leukemia express leukemia-associated antigens: implications for the graft-versus-leukemia effect and peptide vaccine-based immunotherapy. Leukemia 22:1721\u20131727","journal-title":"Leukemia"},{"key":"1126_CR38","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1242\/jcs.022038","volume":"121","author":"CA Maxwell","year":"2008","unstructured":"Maxwell CA, McCarthy J, Turley E (2008) Cell-surface and mitotic-spindle RHAMM: moonlighting or dual oncogenic functions? J Cell Sci 121:925\u2013932","journal-title":"J Cell Sci"},{"key":"1126_CR39","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/S0301-472X(02)00874-3","volume":"30","author":"J Greiner","year":"2002","unstructured":"Greiner J, Ringhoffer M, Taniguchi M et al (2002) Receptor for hyaluronan acid-mediated motility (RHAMM) is a new immunogenic leukemia-associated antigen in acute and chronic myeloid leukemia. Exp Hematol 30:1029\u20131035","journal-title":"Exp Hematol"},{"key":"1126_CR40","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1038\/leu.2010.29","volume":"24","author":"K Giannopoulos","year":"2010","unstructured":"Giannopoulos K, Dmoszynska A, Kowal M et al (2010) Peptide vaccination elicits leukemia-associated antigen-specific cytotoxic CD8+ T-cell responses in patients with chronic lymphocytic leukemia. Leukemia 24:798\u2013805","journal-title":"Leukemia"},{"key":"1126_CR41","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/S0014-5793(00)01112-1","volume":"466","author":"K Watari","year":"2000","unstructured":"Watari K, Tojo A, Nagamura-Inoue T, Nagamura F, Takeshita A, Fukushima T, Motoji T, Tani K, Asano S (2000) Identification of a melanoma antigen, PRAME, as a BCR\/ABL-inducible gene. FEBS Lett 466:367\u2013371","journal-title":"FEBS Lett"},{"key":"1126_CR42","doi-asserted-by":"publisher","first-page":"3299","DOI":"10.1182\/blood-2008-07-170282","volume":"114","author":"VG Oehler","year":"2009","unstructured":"Oehler VG, Guthrie KA, Cummings CL et al (2009) The preferentially expressed antigen in melanoma (PRAME) inhibits myeloid differentiation in normal hematopoietic and leukemic progenitor cells. Blood 114:3299\u20133308","journal-title":"Blood"},{"key":"1126_CR43","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1016\/j.leukres.2010.01.017","volume":"34","author":"D Kanojia","year":"2010","unstructured":"Kanojia D, Garg M, Saini S, Agarwal S, Kumar R, Suri A (2010) Sperm associated antigen 9 expression and humoral response in chronic myeloid leukemia. Leuk Res 34:858\u2013863","journal-title":"Leuk Res"},{"key":"1126_CR44","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/j.leukres.2010.03.013","volume":"34","author":"S Hofmann","year":"2010","unstructured":"Hofmann S, Greiner J (2010) Immunogenic antigens as therapeutic targets against myeloid leukaemic cells. Leuk Res 34:850\u2013851","journal-title":"Leuk Res"},{"key":"1126_CR45","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1002\/med.20203","volume":"31","author":"D Karthigeyan","year":"2011","unstructured":"Karthigeyan D, Prasad SB, Shandilya J, Agrawal S, Kundu TK (2011) Biology of aurora A kinase: implications in cancer manifestation and therapy. Med Res Rev 31:757\u2013793","journal-title":"Med Res Rev"},{"key":"1126_CR46","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1182\/blood-2008-06-164889","volume":"113","author":"T Ochi","year":"2009","unstructured":"Ochi T, Fujiwara H, Suemori K, Azuma T, Yakushijin Y, Hato T, Kuzushima K, Yasukawa M (2009) Aurora-A kinase: a novel target of cellular immunotherapy for leukemia. Blood 113:66\u201374","journal-title":"Blood"},{"key":"1126_CR47","doi-asserted-by":"publisher","first-page":"4655","DOI":"10.1158\/0008-5472.CAN-09-3953","volume":"70","author":"P Cammareri","year":"2010","unstructured":"Cammareri P, Scopelliti A, Todaro M et al (2010) Aurora-a is essential for the tumorigenic capacity and chemoresistance of colorectal cancer stem cells. Cancer Res 70:4655\u20134665","journal-title":"Cancer Res"},{"key":"1126_CR48","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/nature01572","volume":"423","author":"J Lessard","year":"2003","unstructured":"Lessard J, Sauvageau G (2003) Bmi-1 determines the proliferative capacity of normal and leukaemic stem cells. Nature 423:255\u2013260","journal-title":"Nature"},{"key":"1126_CR49","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1182\/blood-2006-12-065599","volume":"110","author":"M Mohty","year":"2007","unstructured":"Mohty M, Yong AS, Szydlo RM, Apperley JF, Melo JV (2007) The polycomb group BMI1 gene is a molecular marker for predicting prognosis of chronic myeloid leukemia. Blood 110:380\u2013383","journal-title":"Blood"},{"key":"1126_CR50","doi-asserted-by":"publisher","first-page":"4621","DOI":"10.1182\/blood-2010-02-270660","volume":"116","author":"A Rizo","year":"2010","unstructured":"Rizo A, Horton SJ, Olthof S et al (2010) BMI1 collaborates with BCR-ABL in leukemic transformation of human CD34+ cells. Blood 116:4621\u20134630","journal-title":"Blood"},{"key":"1126_CR51","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1038\/leu.2010.197","volume":"25","author":"DM Ross","year":"2011","unstructured":"Ross DM, Hughes TP, Melo JV (2011) Do we have to kill the last CML cell? Leukemia 25:193\u2013200","journal-title":"Leukemia"},{"key":"1126_CR52","doi-asserted-by":"publisher","unstructured":"Wu CJ (2008) Immunologic targeting of the cancer stem cell. In: The Stem Cell Research Community (ed) StemBook. doi:10.3824\/stembook.1.21.1, http:\/\/www.stembook.org","DOI":"10.3824\/stembook.1.21.1"},{"key":"1126_CR53","doi-asserted-by":"publisher","first-page":"5342","DOI":"10.1182\/blood-2007-12-128397","volume":"111","author":"CI Chen","year":"2008","unstructured":"Chen CI, Maecker HT, Lee PP (2008) Development and dynamics of robust T-cell responses to CML under imatinib treatment. Blood 111:5342\u20135349","journal-title":"Blood"},{"key":"1126_CR54","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1073\/pnas.94.5.1914","volume":"94","author":"YT Chen","year":"1997","unstructured":"Chen YT, Scanlan MJ, Sahin U et al (1997) A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci USA 94:1914\u20131918","journal-title":"Proc Natl Acad Sci USA"},{"key":"1126_CR55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0065-230X(06)95001-5","volume":"95","author":"S Gnjatic","year":"2006","unstructured":"Gnjatic S, Nishikawa H, Jungbluth AA, Gure AO, Ritter G, Jager E, Knuth A, Chen YT, Old LJ (2006) NY-ESO-1: review of an immunogenic tumor antigen. Adv Cancer Res 95:1\u201330","journal-title":"Adv Cancer Res"},{"key":"1126_CR56","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1182\/blood-2009-07-233445","volume":"115","author":"YW Lin","year":"2010","unstructured":"Lin YW, Beharry ZM, Hill EG et al (2010) A small molecule inhibitor of Pim protein kinases blocks the growth of precursor T-cell lymphoblastic leukemia\/lymphoma. Blood 115:824\u2013833","journal-title":"Blood"},{"key":"1126_CR57","first-page":"362","volume":"119","author":"XF Hu","year":"2009","unstructured":"Hu XF, Li J, Vandervalk S, Wang Z, Magnuson NS, Xing PX (2009) PIM-1-specific mAb suppresses human and mouse tumor growth by decreasing PIM-1 levels, reducing Akt phosphorylation, and activating apoptosis. J Clin Invest 119:362\u2013375","journal-title":"J Clin Invest"},{"key":"1126_CR58","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1038\/sj.onc.1203355","volume":"19","author":"A Eichmann","year":"2000","unstructured":"Eichmann A, Yuan L, Breant C, Alitalo K, Koskinen PJ (2000) Developmental expression of pim kinases suggests functions also outside of the hematopoietic system. Oncogene 19:1215\u20131224","journal-title":"Oncogene"},{"key":"1126_CR59","doi-asserted-by":"publisher","first-page":"4330","DOI":"10.1021\/pr0704128","volume":"6","author":"S Fontana","year":"2007","unstructured":"Fontana S, Alessandro R, Barranca M, Giordano M, Corrado C, Zanella-Cleon I, Becchi M, Kohn EC, De Leo G (2007) Comparative proteome profiling and functional analysis of chronic myelogenous leukemia cell lines. J Proteome Res 6:4330\u20134342","journal-title":"J Proteome Res"},{"key":"1126_CR60","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1182\/blood.V99.6.2037","volume":"99","author":"U Steidl","year":"2002","unstructured":"Steidl U, Kronenwett R, Rohr UP et al (2002) Gene expression profiling identifies significant differences between the molecular phenotypes of bone marrow-derived and circulating human CD34+ hematopoietic stem cells. Blood 99:2037\u20132044","journal-title":"Blood"},{"key":"1126_CR61","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1189\/jlb.0603287","volume":"75","author":"YY Ng","year":"2004","unstructured":"Ng YY, van Kessel B, Lokhorst HM, Baert MR, van den Burg CM, Bloem AC, Staal FJ (2004) Gene-expression profiling of CD34+ cells from various hematopoietic stem-cell sources reveals functional differences in stem-cell activity. J Leukoc Biol 75:314\u2013323","journal-title":"J Leukoc Biol"},{"key":"1126_CR62","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1038\/sj.leu.2404227","volume":"20","author":"C Zheng","year":"2006","unstructured":"Zheng C, Li L, Haak M et al (2006) Gene expression profiling of CD34+ cells identifies a molecular signature of chronic myeloid leukemia blast crisis. Leukemia 20:1028\u20131034","journal-title":"Leukemia"},{"key":"1126_CR63","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1182\/blood-2007-02-071738","volume":"110","author":"AS Yong","year":"2007","unstructured":"Yong AS, Rezvani K, Savani BN, Eniafe R, Mielke S, Goldman JM, Barrett AJ (2007) High PR3 or ELA2 expression by CD34+ cells in advanced-phase chronic myeloid leukemia is associated with improved outcome following allogeneic stem cell transplantation and may improve PR1 peptide-driven graft-versus-leukemia effects. Blood 110:770\u2013775","journal-title":"Blood"},{"key":"1126_CR64","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1038\/sj.leu.2403779","volume":"19","author":"M Giehl","year":"2005","unstructured":"Giehl M, Fabarius A, Frank O, Hochhaus A, Hafner M, Hehlmann R, Seifarth W (2005) Centrosome aberrations in chronic myeloid leukemia correlate with stage of disease and chromosomal instability. Leukemia 19:1192\u20131197","journal-title":"Leukemia"},{"key":"1126_CR65","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1111\/j.1365-2141.2009.07772.x","volume":"146","author":"H Patel","year":"2009","unstructured":"Patel H, Gordon MY (2009) Abnormal centrosome-centriole cycle in chronic myeloid leukaemia? Br J Haematol 146:408\u2013417","journal-title":"Br J Haematol"},{"key":"1126_CR66","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1002\/ajh.21915","volume":"86","author":"JM Gerber","year":"2011","unstructured":"Gerber JM, Qin L, Kowalski J et al (2011) Characterization of chronic myeloid leukemia stem cells. Am J Hematol 86:31\u201337","journal-title":"Am J Hematol"},{"key":"1126_CR67","doi-asserted-by":"publisher","first-page":"3406","DOI":"10.1182\/blood-2006-04-018705","volume":"108","author":"S Mumprecht","year":"2006","unstructured":"Mumprecht S, Matter M, Pavelic V, Ochsenbein AF (2006) Imatinib mesylate selectively impairs expansion of memory cytotoxic T cells without affecting the control of primary viral infections. Blood 108:3406\u20133413","journal-title":"Blood"},{"key":"1126_CR68","doi-asserted-by":"publisher","first-page":"251","DOI":"10.2174\/156800907780618293","volume":"7","author":"D Wolf","year":"2007","unstructured":"Wolf D, Tilg H, Rumpold H, Gastl G, Wolf AM (2007) The kinase inhibitor imatinib\u2014an immunosuppressive drug? Curr Cancer Drug Targets 7:251\u2013258","journal-title":"Curr Cancer Drug Targets"},{"key":"1126_CR69","doi-asserted-by":"publisher","first-page":"e1000095","DOI":"10.1371\/journal.pcbi.1000095","volume":"4","author":"PS Kim","year":"2008","unstructured":"Kim PS, Lee PP, Levy D (2008) Dynamics and potential impact of the immune response to chronic myelogenous leukemia. PLoS Comput Biol 4:e1000095","journal-title":"PLoS Comput Biol"},{"key":"1126_CR70","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/nrclinonc.2009.115","volume":"6","author":"J Barrett","year":"2009","unstructured":"Barrett J, Rezvani K (2009) Immunotherapy: can we include vaccines with stem-cell transplantation? Nat Rev Clin Oncol 6:503\u2013505","journal-title":"Nat Rev Clin Oncol"},{"key":"1126_CR71","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1080\/10428190701471981","volume":"48","author":"ER Plimack","year":"2007","unstructured":"Plimack ER, Kantarjian HM, Issa JP (2007) Decitabine and its role in the treatment of hematopoietic malignancies. Leuk Lymphoma 48:1472\u20131481","journal-title":"Leuk Lymphoma"},{"key":"1126_CR72","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1097\/00002371-199901000-00003","volume":"22","author":"S Coral","year":"1999","unstructured":"Coral S, Sigalotti L, Gasparollo A, Cattarossi I, Visintin A, Cattelan A, Altomonte M, Maio M (1999) Prolonged upregulation of the expression of HLA class I antigens and costimulatory molecules on melanoma cells treated with 5-aza-2\u2032-deoxycytidine (5-AZA-CdR). J Immunother 22:16\u201324","journal-title":"J Immunother"},{"key":"1126_CR73","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1007\/s00262-008-0582-6","volume":"58","author":"SJ Adair","year":"2009","unstructured":"Adair SJ, Hogan KT (2009) Treatment of ovarian cancer cell lines with 5-aza-2\u2032-deoxycytidine upregulates the expression of cancer-testis antigens and class I major histocompatibility complex-encoded molecules. Cancer Immunol Immunother 58:589\u2013601","journal-title":"Cancer Immunol Immunother"},{"key":"1126_CR74","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.1182\/blood-2009-11-249474","volume":"116","author":"O Goodyear","year":"2010","unstructured":"Goodyear O, Agathanggelou A, Novitzky-Basso I et al (2010) Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia. Blood 116:1908\u20131918","journal-title":"Blood"},{"key":"1126_CR75","doi-asserted-by":"publisher","first-page":"174378","DOI":"10.1155\/2010\/174378","volume":"2010","author":"D Fioretti","year":"2010","unstructured":"Fioretti D, Iurescia S, Fazio VM, Rinaldi M (2010) DNA vaccines: developing new strategies against cancer. J Biomed Biotechnol 2010:174378","journal-title":"J Biomed Biotechnol"},{"key":"1126_CR76","doi-asserted-by":"publisher","first-page":"2956","DOI":"10.1182\/blood-2008-02-137695","volume":"112","author":"C Chaise","year":"2008","unstructured":"Chaise C, Buchan SL, Rice J et al (2008) DNA vaccination induces WT1-specific T-cell responses with potential clinical relevance. Blood 112:2956\u20132964","journal-title":"Blood"},{"key":"1126_CR77","doi-asserted-by":"crossref","first-page":"4764","DOI":"10.1182\/blood.V92.12.4764","volume":"92","author":"M Ling","year":"1998","unstructured":"Ling M, Wen YJ, Lim SH (1998) Prevalence of antibodies against proteins derived from leukemia cells in patients with chronic myeloid leukemia. Blood 92:4764\u20134770","journal-title":"Blood"},{"key":"1126_CR78","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1172\/JCI10196","volume":"106","author":"CJ Wu","year":"2000","unstructured":"Wu CJ, Yang XF, McLaughlin S et al (2000) Detection of a potent humoral response associated with immune-induced remission of chronic myelogenous leukemia. J Clin Invest 106:705\u2013714","journal-title":"J Clin Invest"},{"key":"1126_CR79","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1002\/ijc.11200","volume":"106","author":"J Greiner","year":"2003","unstructured":"Greiner J, Ringhoffer M, Taniguchi M, Hauser T, Schmitt A, Dohner H, Schmitt M (2003) Characterization of several leukemia-associated antigens inducing humoral immune responses in acute and chronic myeloid leukemia. Int J Cancer 106:224\u2013231","journal-title":"Int J Cancer"},{"key":"1126_CR80","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1016\/j.bbrc.2005.08.024","volume":"335","author":"BA Guinn","year":"2005","unstructured":"Guinn BA, Bland EA, Lodi U, Liggins AP, Tobal K, Petters S, Wells JW, Banham AH, Mufti GJ (2005) Humoral detection of leukaemia-associated antigens in presentation acute myeloid leukaemia. Biochem Biophys Res Commun 335:1293\u20131304","journal-title":"Biochem Biophys Res Commun"},{"key":"1126_CR81","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1016\/j.exphem.2007.03.015","volume":"35","author":"H Takahashi","year":"2007","unstructured":"Takahashi H, Furukawa T, Yano T et al (2007) Identification of an overexpressed gene, HSPA4L, the product of which can provoke prevalent humoral immune responses in leukemia patients. Exp Hematol 35:1091\u20131099","journal-title":"Exp Hematol"},{"key":"1126_CR82","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1158\/0008-5472.CAN-09-2303","volume":"70","author":"MA Biernacki","year":"2010","unstructured":"Biernacki MA, Marina O, Zhang W et al (2010) Efficacious immune therapy in chronic myelogenous leukemia (CML) recognizes antigens that are expressed on CML progenitor cells. Cancer Res 70:906\u2013915","journal-title":"Cancer Res"},{"key":"1126_CR83","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1016\/j.leukres.2005.04.021","volume":"29","author":"L Zou","year":"2005","unstructured":"Zou L, Wu Y, Pei L et al (2005) Identification of leukemia-associated antigens in chronic myeloid leukemia by proteomic analysis. Leuk Res 29:1387\u20131391","journal-title":"Leuk Res"},{"key":"1126_CR84","doi-asserted-by":"publisher","first-page":"2238","DOI":"10.1038\/sj.leu.2402732","volume":"16","author":"SP Adams","year":"2002","unstructured":"Adams SP, Sahota SS, Mijovic A, Czepulkowski B, Padua RA, Mufti GJ, Guinn BA (2002) Frequent expression of HAGE in presentation chronic myeloid leukaemias. Leukemia 16:2238\u20132242","journal-title":"Leukemia"},{"key":"1126_CR85","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1016\/j.exphem.2006.07.009","volume":"34","author":"M Schmitt","year":"2006","unstructured":"Schmitt M, Li L, Giannopoulos K et al (2006) Chronic myeloid leukemia cells express tumor-associated antigens eliciting specific CD8+ T-cell responses and are lacking costimulatory molecules. Exp Hematol 34:1709\u20131719","journal-title":"Exp Hematol"},{"key":"1126_CR86","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1016\/j.leukres.2010.03.039","volume":"34","author":"T Luetkens","year":"2010","unstructured":"Luetkens T, Schafhausen P, Uhlich F et al (2010) Expression, epigenetic regulation, and humoral immunogenicity of cancer-testis antigens in chronic myeloid leukemia. Leuk Res 34:1647\u20131655","journal-title":"Leuk Res"},{"key":"1126_CR87","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1038\/sj.bjc.6690824","volume":"81","author":"SH Lim","year":"1999","unstructured":"Lim SH, Austin S, Owen-Jones E, Robinson L (1999) Expression of testicular genes in haematological malignancies. Br J Cancer 81:1162\u20131164","journal-title":"Br J Cancer"},{"key":"1126_CR88","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.leukres.2006.05.009","volume":"31","author":"A Martinez","year":"2007","unstructured":"Martinez A, Olarte I, Mergold MA et al (2007) mRNA expression of MAGE-A3 gene in leukemia cells. Leuk Res 31:33\u201337","journal-title":"Leuk Res"},{"key":"1126_CR89","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.leukres.2006.06.022","volume":"31","author":"S Paydas","year":"2007","unstructured":"Paydas S, Tanriverdi K, Yavuz S, Seydaoglu G (2007) PRAME mRNA levels in cases with chronic leukemia: clinical importance and review of the literature. Leuk Res 31:365\u2013369","journal-title":"Leuk Res"},{"key":"1126_CR90","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1097\/00002371-200311000-00001","volume":"26","author":"Y Zhang","year":"2003","unstructured":"Zhang Y, Wang Z, Liu H, Giles FJ, Lim SH (2003) Pattern of gene expression and immune responses to Semenogelin 1 in chronic hematologic malignancies. J Immunother 26:461\u2013467","journal-title":"J Immunother"},{"key":"1126_CR91","doi-asserted-by":"publisher","first-page":"6544","DOI":"10.1158\/1078-0432.CCR-04-0911","volume":"10","author":"Z Wang","year":"2004","unstructured":"Wang Z, Zhang Y, Mandal A, Zhang J, Giles FJ, Herr JC, Lim SH (2004) The spermatozoa protein, SLLP1, is a novel cancer-testis antigen in hematologic malignancies. Clin Cancer Res 10:6544\u20136550","journal-title":"Clin Cancer Res"},{"key":"1126_CR92","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1182\/blood-2002-06-1930","volume":"101","author":"Z Wang","year":"2003","unstructured":"Wang Z, Zhang Y, Liu H, Salati E, Chiriva-Internati M, Lim SH (2003) Gene expression and immunologic consequence of SPAN-Xb in myeloma and other hematologic malignancies. Blood 101:955\u2013960","journal-title":"Blood"},{"key":"1126_CR93","doi-asserted-by":"publisher","first-page":"5287","DOI":"10.1073\/pnas.92.12.5287","volume":"92","author":"I Sanchez-Garcia","year":"1995","unstructured":"Sanchez-Garcia I, Grutz G (1995) Tumorigenic activity of the BCR-ABL oncogenes is mediated by BCL2. Proc Natl Acad Sci USA 92:5287\u20135291","journal-title":"Proc Natl Acad Sci USA"},{"key":"1126_CR94","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/S0301-472X(02)00808-1","volume":"30","author":"T Nosaka","year":"2002","unstructured":"Nosaka T, Kitamura T (2002) Pim-1 expression is sufficient to induce cytokine independence in murine hematopoietic cells, but is dispensable for BCR-ABL-mediated transformation. Exp Hematol 30:697\u2013702","journal-title":"Exp Hematol"},{"key":"1126_CR95","doi-asserted-by":"publisher","first-page":"7774","DOI":"10.1038\/sj.onc.1206901","volume":"22","author":"R Nawata","year":"2003","unstructured":"Nawata R, Yujiri T, Nakamura Y, Ariyoshi K, Takahashi T, Sato Y, Oka Y, Tanizawa Y (2003) MEK kinase 1 mediates the antiapoptotic effect of the Bcr-Abl oncogene through NF-kappaB activation. Oncogene 22:7774\u20137780","journal-title":"Oncogene"},{"key":"1126_CR96","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1038\/sj.leu.2403255","volume":"18","author":"P Hakansson","year":"2004","unstructured":"Hakansson P, Lassen C, Olofsson T, Baldetorp B, Karlsson A, Gullberg U, Fioretos T (2004) Establishment and phenotypic characterization of human U937 cells with inducible P210 BCR\/ABL expression reveals upregulation of CEACAM1 (CD66a). Leukemia 18:538\u2013547","journal-title":"Leukemia"},{"key":"1126_CR97","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1002\/cncr.20457","volume":"101","author":"D Cilloni","year":"2004","unstructured":"Cilloni D, Messa F, Gottardi E et al (2004) Sensitivity to imatinib therapy may be predicted by testing Wilms tumor gene expression and colony growth after a short in vitro incubation. Cancer 101:979\u2013988","journal-title":"Cancer"},{"key":"1126_CR98","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1002\/gcc.20528","volume":"47","author":"P Hakansson","year":"2008","unstructured":"Hakansson P, Nilsson B, Andersson A, Lassen C, Gullberg U, Fioretos T (2008) Gene expression analysis of BCR\/ABL1-dependent transcriptional response reveals enrichment for genes involved in negative feedback regulation. Genes Chromosom Cancer 47:267\u2013275","journal-title":"Genes Chromosom Cancer"},{"key":"1126_CR99","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1038\/leu.2008.337","volume":"23","author":"D Bruennert","year":"2009","unstructured":"Bruennert D, Czibere A, Bruns I, Kronenwett R, Gattermann N, Haas R, Neumann F (2009) Early in vivo changes of the transcriptome in Philadelphia chromosome-positive CD34+ cells from patients with chronic myelogenous leukaemia following imatinib therapy. Leukemia 23:983\u2013985","journal-title":"Leukemia"},{"key":"1126_CR100","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s00277-008-0603-8","volume":"88","author":"J Bhattacharyya","year":"2009","unstructured":"Bhattacharyya J, Mihara K, Yasunaga S, Tanaka H, Hoshi M, Takihara Y, Kimura A (2009) BMI-1 expression is enhanced through transcriptional and posttranscriptional regulation during the progression of chronic myeloid leukemia. Ann Hematol 88:333\u2013340","journal-title":"Ann Hematol"},{"key":"1126_CR101","doi-asserted-by":"publisher","first-page":"3111","DOI":"10.1634\/stemcells.2007-0250","volume":"25","author":"SM Graham","year":"2007","unstructured":"Graham SM, Vass JK, Holyoake TL, Graham GJ (2007) Transcriptional analysis of quiescent and proliferating CD34+ human hemopoietic cells from normal and chronic myeloid leukemia sources. Stem Cells 25:3111\u20133120","journal-title":"Stem Cells"},{"key":"1126_CR102","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1038\/leu.2008.392","volume":"23","author":"I Bruns","year":"2009","unstructured":"Bruns I, Czibere A, Fischer JC et al (2009) The hematopoietic stem cell in chronic phase CML is characterized by a transcriptional profile resembling normal myeloid progenitor cells and reflecting loss of quiescence. Leukemia 23:892\u2013899","journal-title":"Leukemia"},{"key":"1126_CR1000","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/86730","volume":"19","author":"TR Hughes","year":"2001","unstructured":"Hughes TR, Mao M, Jones AR et al (2001) Expression profiling using microarrays fabricated by an ink-jet oligonucleotide synthesizer. Nat Biotechnol 19:342\u2013347","journal-title":"Nat Biotechnol"},{"key":"1126_CR103","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1002\/ijc.11623","volume":"108","author":"J Greiner","year":"2004","unstructured":"Greiner J, Ringhoffer M, Taniguchi M, Li L, Schmitt A, Shiku H, Dohner H, Schmitt M (2004) mRNA expression of leukemia-associated antigens in patients with acute myeloid leukemia for the development of specific immunotherapies. Int J Cancer 108:704\u2013711","journal-title":"Int J Cancer"},{"key":"1126_CR104","doi-asserted-by":"publisher","first-page":"3272","DOI":"10.1182\/blood.V99.9.3272","volume":"99","author":"OA Elisseeva","year":"2002","unstructured":"Elisseeva OA, Oka Y, Tsuboi A et al (2002) Humoral immune responses against Wilms tumor gene WT1 product in patients with hematopoietic malignancies. Blood 99:3272\u20133279","journal-title":"Blood"},{"key":"1126_CR105","doi-asserted-by":"crossref","first-page":"2878","DOI":"10.1182\/blood.V87.7.2878.bloodjournal8772878","volume":"87","author":"T Yamagami","year":"1996","unstructured":"Yamagami T, Sugiyama H, Inoue K et al (1996) Growth inhibition of human leukemic cells by WT1 (Wilms tumor gene) antisense oligodeoxynucleotides: implications for the involvement of WT1 in leukemogenesis. Blood 87:2878\u20132884","journal-title":"Blood"},{"key":"1126_CR106","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1038\/79526","volume":"6","author":"JJ Molldrem","year":"2000","unstructured":"Molldrem JJ, Lee PP, Wang C, Felio K, Kantarjian HM, Champlin RE, Davis MM (2000) Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat Med 6:1018\u20131023","journal-title":"Nat Med"},{"key":"1126_CR107","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/0092-8674(89)90752-6","volume":"59","author":"D Bories","year":"1989","unstructured":"Bories D, Raynal MC, Solomon DH, Darzynkiewicz Z, Cayre YE (1989) Down-regulation of a serine protease, myeloblastin, causes growth arrest and differentiation of promyelocytic leukemia cells. Cell 59:959\u2013968","journal-title":"Cell"},{"key":"1126_CR108","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1016\/j.leukres.2007.02.016","volume":"31","author":"J Roman-Gomez","year":"2007","unstructured":"Roman-Gomez J, Jimenez-Velasco A, Agirre X et al (2007) Epigenetic regulation of PRAME gene in chronic myeloid leukemia. Leuk Res 31:1521\u20131528","journal-title":"Leuk Res"},{"key":"1126_CR109","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1182\/blood-2008-03-144071","volume":"113","author":"K Rezvani","year":"2009","unstructured":"Rezvani K, Yong AS, Tawab A et al (2009) Ex vivo characterization of polyclonal memory CD8+ T-cell responses to PRAME-specific peptides in patients with acute lymphoblastic leukemia and acute and chronic myeloid leukemia. Blood 113:2245\u20132255","journal-title":"Blood"},{"key":"1126_CR110","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/j.cell.2005.07.003","volume":"122","author":"MT Epping","year":"2005","unstructured":"Epping MT, Wang L, Edel MJ, Carlee L, Hernandez M, Bernards R (2005) The human tumor antigen PRAME is a dominant repressor of retinoic acid receptor signaling. Cell 122:835\u2013847","journal-title":"Cell"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-011-1126-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-011-1126-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-011-1126-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-011-1126-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T13:01:00Z","timestamp":1744030860000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-011-1126-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10,28]]},"references-count":111,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["1126"],"URL":"https:\/\/doi.org\/10.1007\/s00262-011-1126-z","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,10,28]]},"assertion":[{"value":"20 July 2011","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2011","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2011","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}